The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations
Authors:
- 21 December 2021
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (5) , e153-e158
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Clinical Microbiology and Infection, 2021
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19New England Journal of Medicine, 2021
- Trends in COVID-19 therapeutic clinical trialsNature Reviews Drug Discovery, 2021
- Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2021
- Hydroxychloroquine for COVID-19: Balancing contrasting claimsEuropean Journal of Internal Medicine, 2020
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19JAMA, 2020
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2020
- A living WHO guideline on drugs for covid-19 (2020-2023)BMJ, 2020
- The Magic of Randomization versus the Myth of Real-World EvidenceNew England Journal of Medicine, 2020
- The social history of ISIS-2: the early historyThe Lancet, 2015